Results 81 to 90 of about 2,874 (159)

Characterization of Enterobacter cloacae and Citrobacter freundii Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam–Avibactam and Comparator Agents (2019–2023)

Antibiotics
Background: Citrobacter freundii (CFC) and Enterobacter cloacae (ECLC) species complexes represent important causes of hospital-associated infections, frequently are related to outbreaks, and have a great ability to develop antimicrobial resistance.
Helio S. Sader, Timothy B. Doyle, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +4 more
doaj   +1 more source

Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018–2021

Journal of Microbiology, Immunology and Infection
Background: The coronavirus disease 2019 (COVID-19) pandemic has contributed to the spread of antimicrobial resistance, including carbapenem-resistant Enterobacterales.
Yu-Lin Lee, Chun-Eng Liu, Hung-Jen Tang, Yu-Tsung Huang, Yao-Shen Chen, Po-Ren Hsueh, Wen-Chien Ko, Po-Liang Lu, Chun-Eng Liu, Kenneth Yin-Ching Chuang, Fu-Der Wang, Yao-Shen Chen, Min-Chi Lu, Mao-Wang Ho   +13 more
doaj   +1 more source

Η εφαρμογή του νέου αναστολέα vaborbactam στη θεραπευτική των λοιμώξεων

, 2022
Οι λοιμώξεις από ανθεκτικά στις καρβαπενέμες Enterobacterales, Pseudomonas aeruginosa, και Acinetobacter baumannii αποτελούν απειλή για τη δημόσια υγεία παγκοσμίως, και σχετίζονται με αυξημένη νοσηρότητα και θνητότητα. Η αντοχή οφείλεται κυρίως στην παραγωγή καρβαπενεμασών. Η βαμπορβακτάμη είναι ένας νέος αναστολέας β-λακταμασών.
openaire   +1 more source

Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection

Infection and Drug Resistance
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj  

Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion. [PDF]

Pharmaceutics
Trozzi I, Giorgi B, De Paola R, Gatti M, Pea F.   +4 more
europepmc   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. [PDF]

Antimicrob Agents Chemother
Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K.   +5 more
europepmc   +1 more source

Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]

Front Microbiol
Frontiers Production Office.
europepmc   +1 more source

Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]

Antimicrob Agents Chemother
Mohammad S, Al Namer Y, Rahimeh W, Albalas M, Almangour TA.   +4 more
europepmc   +1 more source

From bugs to bots: learning infectious diseases in the AI era. [PDF]

Antimicrob Steward Healthc Epidemiol
Rodriguez-Nava G.
europepmc   +1 more source

In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis

Journal of Antimicrobial Chemotherapy, 2019
Wesley D Kufel, Ambika P Eranki, Kristopher M Paolino, Andrea Call, Christopher D Miller, Bryan T Mogle   +5 more
openaire   +2 more sources